Superseded public profile
Superseded · version 1: GHRP-2↗↗
Related names recorded in this version: Pralmorelin, Growth hormone-releasing peptide 2↗
A synthetic six-amino-acid growth hormone secretagogue, also called pralmorelin, that FDA lists among compounding substances that may present significant safety risks.↗↗
It is no longer the current profile. Read the canonical profile and its correction notice.
What this version reported
FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported in the cited sources, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗
Reader guide in this version
Key takeaway
GHRP-2 (growth hormone-releasing peptide 2) is a synthetic six-amino-acid peptide that FDA’s substance registry lists under the international name pralmorelin.1 FDA has placed GHRP-2 in category 2 of its compounding lists, for substances that may present significant safety risks, citing possible immune reactions and reports of serious adverse events, including deaths of critically ill study participants, though causality has not been established.2 No FDA approval is reported in the sources reviewed here, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4
At a glance
- What it is
- A synthetic hexapeptide amide (D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2), also recorded as pralmorelin and KP-102, according to FDA’s substance registry.1
- FDA status
- No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-2 in category 2 under its interim policy for outsourcing facilities, for substances that may present significant safety risks.2
- Human evidence
- FDA reports being aware of serious adverse events in patients who received GHRP-2. The FDA sources reviewed here do not describe controlled trials of it.2
- Evidence strength
- Limited human data
What is GHRP-2?
GHRP-2 is a synthetic peptide of six amino acids, several of them in the unnatural D form, ending in an amide. FDA’s substance registry records it as pralmorelin, growth hormone-releasing peptide 2 and KP-102.1
FDA notes that GHRP-2 contains an unnatural amino acid, which makes the peptide harder to characterize.2
How is GHRP-2 thought to work?
Its registered name, growth hormone-releasing peptide 2, describes its intended action of prompting the release of growth hormone.1
The FDA sources reviewed here do not describe its mechanism or present studies of its effects.1,2
What do human studies show?
FDA reports being aware of serious adverse events in patients who received GHRP-2, including a greater need for insulin to control blood sugar, deaths of critically ill study participants, infection and pancreatitis, though causality has not been established.2
The FDA sources reviewed here do not evaluate whether GHRP-2 is effective for any use.2
What the evidence base contains
- Small, short, or incompletely reported human study Reports, cited by FDA, of serious adverse events in patients who received GHRP-2, including higher insulin needs, deaths of critically ill study participants, infection and pancreatitis, with causality not established.2
Evidence-strength label: Limited human data. How this label is assigned
Is GHRP-2 FDA-approved?
None of the sources reviewed here reports an approval of GHRP-2 by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-2 in category 2 under the interim policy for outsourcing facilities (section 503B) for certain routes since September 29, 2023, citing possible immune reactions from aggregation and impurities.2
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-2 is not among them.3,4
What is still unknown?
Whether it is effective for any condition, which no FDA source reviewed here has evaluated.2
Whether the serious adverse events FDA describes were caused by GHRP-2, which FDA states has not been established.2
Sources for this version
- 1Pralmorelin (GHRP-2) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026